A practical reference on LC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
==== In adolescence ==== There has been a significant focus in past research on adulthood, in regards to well-being and development and although eudaimonia is not a new field of study, there has been little research done in the areas of adolescence and youth. Research that has been done on this age group had previously explored more negative aspects than well-being, such as problem and risk behaviours (i.e. drug and alcohol use). Researchers who conducted a study in 2013 recognized the absence of adolescents in eudaimonic research and the importance of this developmental stage. Adolescents rapidly face cognitive, social and physical changes, making them prime subjects to study for development and well-being. The eudaimonic identity theory was used in their research to examine the development of identity through self-discovery and self-realization. They emphasize the personal value found in discovering and appeasing one's "daimon" (daemon) through subjective experiences that develop eudaimonic happiness from aligning with one's true self. Researchers focused their studies on PYD (positive youth development) and the eudaimonic identity theory in the context of three developmental elements: self-defining activities, personal expressiveness and goal-directed behaviours. They determined that adolescents sample multiple self-defining activities; these activities aid in identity formation, as individuals choose activities that they believe represents who they are. These self-defining activities also help determine the adolescent's social environments.
== Education and career == Brodbelt has an undergraduate degree from the University of Virginia and earned her Ph.D. from Purdue University where she worked on gas phase ion chemistry using mass spectrometry. Following her Ph.D. she was a postdoc at the University of California, Santa Barbara before joining the University of Texas at Austin in 1989. As of 2016, she is the Roland Pettit Centennial Chair in the Department of Chemistry. She was the president of the American Society for Mass Spectrometry from 2014 to 2016.
=== Casting === Merle Dandridge reprised her role as Alyx for initial recording sessions in March 2019, but after playtests indicated that Alyx needed a younger voice, Ozioma Akagha was cast in September 2019. Akagha avoided using irritation in her performance, as "you don't want someone in your head that sounds irritated with you". Additional actors include James Moses Black as Eli, replacing Robert Guillaume, who died in 2017, and Rhys Darby as Russell, who added comedic elements. Returning actors include Tony Todd as the alien Vortigaunts, Mike Shapiro as the G-Man, and Ellen McLain as the voice of the Combine broadcasts. Shapiro recorded his lines in one 20-minute take, with pickups in 2019. Cissy Jones (Olga) and Rich Sommer (Larry, Russell's drone, and Combine Soldiers) were cast at the suggestion of the writer Sean Vanaman, who had worked with them on Campo Santo's Firewatch (2016).
== Additional biological roles == Stress-induced adrenal hormone increase may upregulate GnIH release, as some GnIH neurons have adrenal glucocorticoid receptors. GnIH may therefore mediate interactions between the HPG and HPA (hypothalamic-pituitary-adrenal) axes and play a role in stress-related infertility. GnIH neurons of the paraventricular nucleus in the hypothalamus also express melatonin receptors. Because melatonin secretion is modulated by environmental light patterns, melatonin influence on GnIH production may enable photoperiodic regulation of reproduction in seasonally breeding birds, rodents, and sheep. GnIH increases food consumption, implying a role in appetite. This finding is consistent with the location of most GnIH neurons, as the dorsomedial nucleus of the hypothalamus is involved in appetite regulation. GnIH may allow the energy reserves of an organism to modulate reproduction. Higher levels of thyroid hormone suppress GnIH expression, and lower levels of thyroid hormone are associated with higher GnIH levels. The inactivation of GnIH expression prevents delayed puberty caused by hypothyroidism, demonstrating that GnIH mediates interactions between the HPG and HPT (hypothalamic-pituitary-thyroid) axes. Furthermore, thyroid hormone may function in a pathway for photoperiodic regulation of reproduction involving GnIH and energy status. Melatonin modulates thyroid-stimulating hormone (TSH) production in the anterior pituitary, and TSH promotes thyroid hormone production.
Sources: en.wikipedia.org
The mouth of the sand dollar is located on the bottom of its body at the center of the petal-like pattern. Unlike other urchins, the bodies of sand dollars also display secondary front-to-back bilateral symmetry with no morphological distinguishing features between males and females. The anus of sand dollars is located at the back rather than at the top as in most urchins, with many more bilateral features appearing in some species. These result from the adaptation of sand dollars, in the course of their evolution, from creatures that originally lived their lives on top of the seabed (epibenthos) to creatures that burrow beneath it (endobenthos).
These women will often be blamed for their child's diagnosis of sickle cell disease, especially if sickle cell disease is not present in earlier generations, due to the suspicion that the child's poor health may have been caused by the mother's failure to implement preventative health measures or promote a healthy environment for her child to thrive. The reliance on theories related to environmental factors to place blame on the mother reflects many Ugandans' poor knowledge of how the disease is acquired as it is determined by genetics, not environment. Mothers of children with sickle cell disease are also often left with very limited resources to safeguard their futures against the stigma of having sickle cell disease. This lack of access to resources results from their subordinating roles within familial structures as well as the class disparities that hinder many mothers' ability to satisfy additional childcare costs and responsibilities. Women living with sickle cell disease who become pregnant often face extreme discrimination and discouragement in Uganda. These women are frequently branded by their peers as irresponsible for having a baby while living with sickle cell disease or even engaging in sex while living with sickle cell disease. The criticism and judgement these women receive, not only from healthcare professionals but also from their families, often leaves them feeling alone, depressed, anxious, ashamed, and with very little social support.
Rockefeller Benjamin Jealous (1994), president of the NAACP Ai-jen Poo (1996), activist, recipient of the MacArthur Fellowship in 2014 Risë Wilson (1997), activist Anna Baltzer (2002), activist for Palestinian human rights Ady Barkan (2006), activist and organizer for Center for Popular Democracy Tourmaline (2006), activist and filmmaker Emma Sulkowicz (2015), performance activist known for Mattress Performance (Carry That Weight) and Ceci N'est Pas Un Viol Coleman Hughes (2020), activist and writer on issues of race and racism Henry Williams (2022), political activist and chief of staff of the Mike Gravel 2020 presidential campaign
Excess matrix metalloproteinases, which are released by leukocytes, may also cause wounds to become chronic. MMPs break down ECM molecules, growth factors, and protease inhibitors, and thus increase degradation while reducing construction, throwing the delicate compromise between production and degradation out of balance.
==== United States ==== Between 1973 and 1978, eleven states decriminalized marijuana. In 2001, Nevada reduced marijuana possession to a misdemeanor and since 2012, several other states have decriminalized and even legalized marijuana. In 2018, surveys indicated that almost half of the people in the United States had tried marijuana, 16% had used it in the past year, and 11% had used it in the past month. In 2014, surveys said daily marijuana use amongst US college students had reached its highest level since records began in 1980, rising from 3.5% in 2007 to 5.9% in 2014 and had surpassed daily cigarette use. In the US, men are over twice as likely to use marijuana as women, and 18–29-year-olds are six times more likely to use as over-65-year-olds. In 2015, a record 44% of the US population has tried marijuana in their lifetime, an increase from 38% in 2013 and 33% in 1985. Marijuana use in the United States is three times above the global average, but in line with other Western democracies. Forty-four percent of American 12th graders have tried the drug at least once, and the typical age of first-use is 16, similar to the typical age of first-use for alcohol but lower than the first-use age for other illicit drugs. A 2022 Gallup poll concluded Americans are smoking more marijuana than cigarettes for the first time.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.